Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates with Phylogenetic Distance from HPV Vaccine Types 16 and 18

Johannes A. Bogaards, Pascal van der Weele, Petra J. Woestenberg, Birgit H. B. van Benthem, Audrey J. King

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and-18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31,-33,-35,-45,-52, and possibly-58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or-18.
Original languageEnglish
Pages (from-to)1141-1146
JournalJournal of Infectious Diseases
Volume220
Issue number7
DOIs
Publication statusPublished - 30 Aug 2019
Externally publishedYes

Cite this